The single use bioreactors market, valued at USD 4.32 billion in 2025, is projected to reach USD 4.81 billion in 2026 and USD 10.48 billion by 2035, with a CAGR of 9.03% during the forecast period, 2026 to 2035. The ongoing technological advancements focused on the development of improved versions of biosensors and single use bioreactor bags are likely to encourage the biopharmaceutical companies to adopt disposable bioreactors for continuous bioprocessing, representing a lucrative opportunity f...

The global DNA synthesis market, valued at USD 1.20 billion in 2025, is projected to reach USD 1.46 billion in 2026 and USD 8.63 billion by 2035, with a 22% CAGR during the forecast period 2026 to 2035. It is worth mentioning that a significant driver propelling the global DNA synthesis market is the increasing requirement for synthetic oligonucleotides such as DNA or RNA to develop therapies, including gene therapies, RNA-based therapies, and targeted therapies. Driven by the growing usage of...

The global gene switch market, valued at USD 795 million in 2025, is projected to reach USD 899 million in 2026 and USD 2,478 billion by 2035, with a 11.93% CAGR during the forecast period 2026 to 2035. Notably, in the past few years, close to 30 cell and gene therapy products have been approved by the US FDA. In addition, over 1,200 cell therapies are currently being evaluated across various clinical stages of development. However, despite various advantages, adverse events are associated with...

The global cell and gene therapy supply chain software market, valued at USD 312 million in 2025, is projected to reach USD 356 million in 2026 and USD 1,329 million by 2035, representing a CAGR of 15.8% during the forecast period 2026 to 2035. According to a report published by Novotech, it was anticipated that more than 12 novel cell and gene therapies would be approved by the end of 2023, highlighting lucrative opportunities for stakeholders in this market. Moreover, post-2018, over 40% of th...

The cell culture media market, valued at USD 9.0 billion in 2025, is projected to reach USD 9.7 billion in 2026 and USD 17.5 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. In July 2024, Merck KGaA invested EUR 6.6 million at Jiangsu, China site to expand the cell culture media manufacturing and production capabilities. In October 2024, Evonik established a global competence network for cell culture solutions in order to increase its offering of system solut...

With accelerated approval from the USFDA, several industrial players are taking strategic initiatives for technological innovations that help to explore more applications autologous cell therapies beyond cancer and autoimmune diseases. For instance, in November 2024, Nature Cell (a Korean biotechnology company) announced the success of autologous adipose stem cells that are delivered into spinal cavity of patient to treat Parkinson’s disease. This therapy has been developed by Japan Angel Stem...

The global single-use consumables market, valued at USD 3.42 billion in 2024, is projected to reach USD 4.02 billion in 2025 and USD 15.19 billion by 2035, representing a CAGR of 14.2% during the forecast period. The global market is categorized across different types of materials, such as metals, plastics, glass, biodegradable materials and other materials. Currently, plastics segment holds the highest share (65%) of the market. Based on the end user, the global market is segmented into biophar...

The global cell therapy packaging market, valued at USD 404 million in 2025, is projected to reach USD 456 million in 2026 and USD 1,225 million by 2035, with a 11.6% CAGR during the forecast period 2026 to 2035. According to our projections, Asia-Pacific captures the major share (41%) in cell therapy packaging market and this trend is unlikely to change in the future. It is further worth highlighting that the cell therapy packaging in Europe is expected to grow at a relatively healthy CAGR (...

The global cell and gene therapy manufacturing market size, valued at USD 11.9 billion in 2024, is projected to reach USD 15.1 billion in 2025 and USD 160.0 billion by 2035, representing a CAGR of 26.64% during the forecast period. According to our projection, North America has the highest share (45%) of the market and the trend of dominance is likely to remain unchanged during the forecast period. North American region is currently dominating the industry with the highest share of 45%. . Accord...

The global viral vector manufacturing market, valued at USD 704 million in 2024, is estimated to reach USD 799 million in 2025 and USD 2,315 million by 2035, representing a CAGR of 11.23% during the forecast period. Over the past few years, these vectors have emerged as the key pre-requisites for cell and gene therapy manufacturing. It is worth mentioning that, till January 2023, over 25 viral vector based gene therapy products have been approved by different regulatory agencies, worldwide. In t...

The continuous adoption of disposable mixer for bioreactor feed preparation offers a competitive advantage to market players to meet future demands and requirement of technological innovations. It is worth mentioning that the current focus will be on advanced sensor integration for real-time process optimization. In addition, numerous industrial players are emphasizing integrating artificial intelligence with single-use mixer for quality control and process optimization.For instance, in March 2...

These 3D cell culture models and organoids are used for studying drug safety and efficacy. In addition to clinical studies, the growing focus on stem cell therapy and regenerative medicine has further bolstered the demand for advanced 3D cell cultures and organoids.Considering the significances of advanced technology-based models, several industrial players are aiming to develop advanced organoid technologies and platforms for drug discovery and clinical studies. For instance, in July 2025, MD A...

The global genome editing market, valued at $4.25 billion in 2025, is projected to reach $5.29 billion in 2026 and $13.36 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035. more than 1,100 active clinical trials are evaluating gene therapies across various phases of clinical studies. According to the World Health Organization (WHO), 10 out of every 1,000 individuals are affected by genetic disorders, with over 70 million people worldwide living with such condi...

The global 3D cell culture market, valued at USD 2.16 billion in 2025, is projected to reach USD 2.61 billion in 2026 and USD 8.90 billion by 2035, with a 14.6% CAGR during the forecast period 2026 to 2035. Driven by the increasing requirement of animal model alternatives, the 3D cell culture market is anticipated to grow at a higher rate during the forecast period. According to our projection, use of 3d cell culture systems for cancer research is dominating the market and is likely to hold 41%...

The global healthcare cold chain logistics market is estimated to grow from USD 197.7 billion in 2024 to reach USD 207.0 billion in 2025 and USD 320.9 billion by 2035, representing a higher CAGR of 4.5% during the forecast period. Given the recent technical breakthroughs and advances, and the steadily rising demand for biopharmaceuticals, the reliance on cold chain is expected to increase substantially, causing logistics service providers to contemplate, devise and implement flexible business st...

The global T-cell therapy market, valued at USD 6.5 billion in 2025, is projected to grow to USD 8.1 billion in 2026 and USD 20.9 billion by 2035, representing a CAGR of 11.2% during the forecast period 2026 to 2035. According to NIH, in 2024, around 2 million people are estimated to be diagnosed with various types of cancer in the U.S. alone. The US FDA approved multiple T cell therapies targeting cancer (in reverse chronological order), such as Obecabtagene autoleucel / Aucatzyl (relapsed or r...

The industrial players such as Merck, Thermo Fisher Scientific and STEMCELL Technologies are increasingly emphasizing adult stem cells specifically those collected from adipose tissues / bone marrow to repair tissue damage and development of stem cell therapies for targeting wide range of diseases. In April 2025, Abu Dhabi Biobank launched an affordable private cord blood banking which offers an affordable and accessible way to preserve their newborns stem cells.

The global TIL therapy market, valued at USD 0.3 billion in 2025, is projected to reach USD 0.6 billion in 2026 and USD 4.2 billion by 2035, with a 23.4% CAGR during the forecast period 2026 to 2035. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, Natural killer cell therapies and macrophages isolated from the tumor. Notably, over 75 TIL cell therapy are being evaluated across different stages of preclinical / clinical development, either as mono...

The TCR therapy market, valued at USD 442 million in 2025, is projected to reach USD 533 million in 2026 and USD 1,563 million by 2035, with a 12.7% CAGR during the forecast period 2026 to 2035, mainly driven by the need for targeted cancer treatment for solid tumors. Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 T cell receptor based immunotherapies for the treatment of various oncological and non-oncological disorders. Furt...

The biopreservation market for media, valued at USD 1.9 billion in 2025, is projected to reach USD 2.3 billion in 2026 and USD 15.5 billion by 2035, with a 23.6% CAGR during the forecast period 2026 to 2035. At present, over 60 players claim to offer more than 190 biopreservation and biobanking, intended for storage and preservation of different types of biological samples. Further, as per a study conducted by the USFDA, across more than 80% submissions for mesenchymal cell-based therapies, it w...